Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 281.222.1782
To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verif ... Read more >
Status: Enrolling
Investigator: Gustavo Roman
Study Coordinator:
Phone:
This is a Phase IIa, randomized, double-blinded, placebo-controlled trial to determine the tolerability of L-serine for Mild Cognitive Impairment patients and assess preliminary indications of efficacy. Efficacy will be assessed by cognitive tes ... Read more >
Status: Enrolling
Investigator: Stanley Appel
Study Coordinator: Aramide Balogun
Phone: 713.441.6937
The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Maushami Gurung
Phone: 346.238.1565
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administere ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator:
Phone:
The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging ... Read more >
Status: Open Not Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Manuel Navarro
Phone: 346.238.1564
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]). ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Chimaoge Onyechi
Phone: 713.363.7729
Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mech ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Andrea Franco Pando
Phone: 713.441.1150
The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abiliti ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Elsa Ruiz
Phone: 713.441.150
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator:
Phone:
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 281.222.1782
The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Maushami Gurung
Phone: 346.238.1565
The purpose of this platform study is to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease. Additionally, the safety and tolerability of these anti-inflammatory agents and the effects on central and periph ... Read more >
